# Commercial QC Panels for Microbiology A commercial QC panel is a pre-characterized, packaged set of control organisms or control materials that verifies your test system is working, while proficiency testing is an external, blinded sample set that verifies your laboratory as a whole. The rule of thumb is simple. Use commercial QC panels every time the test runs, use external proficiency panels on the schedule your accreditation body demands, and never confuse one for the other. This article is a bench-level comparison of the commercial QC panel options a [clinical microbiology](/knowledge/diagnostics/microbiology/clinical-microbiology-from-specimen-collection-to-pathogen-identification) laboratory actually buys and uses. It explains what each panel type contains, where it fits into microbiology quality control and laboratory quality management, the pros and cons that decide real purchasing choices, and the mistakes that most often produce failed QC and unnecessary repeat work. ## Why Microbiology Quality Control Depends on Panels Microbiology quality control answers one question every single day. Is this test system, today, in this laboratory, producing results that match the performance the manufacturer and the standards bodies described when the method was validated? The Clinical and Laboratory Standards Institute (CLSI) publishes reference methods for antimicrobial susceptibility testing, including broth microdilution as the reference MIC method, and publishes the QC ranges that reference strains must fall within for each antimicrobial agent [1]. A QC range is a defined dilution interval, for example three consecutive twofold dilutions, within which a specific reference strain must give its MIC or zone diameter when the test is performed correctly. If the reference strain lands inside the range, the reagents, incubation conditions, inoculum density, incubator temperature, and reading technique were all adequate. If it lands outside, one of those variables failed, and patient results from that run are suspect. Commercial QC panels exist because preparing controls yourself is labor-intensive, error-prone, and hard to trace. A commercial panel arrives as a standardized, often lyophilized preparation of a defined strain, with documented passage history, expected results, and, where applicable, published QC ranges. The laboratory reconstitutes or inoculates the panel exactly as it would a patient isolate. The result either matches the assigned interval or it does not. That pass-or-fail behavior is the entire point. A multicenter evaluation of the Liofilchem Compact Antimicrobial Susceptibility Panel (ComASP) Cefiderocol illustrates how this works in practice. Four sites performed QC with both the panel and CLSI broth microdilution alongside their reproducibility work. All QC results fell within the CLSI QC ranges by both methods, with the exception of two Escherichia coli ATCC 25922 results from one site, which flagged a site-specific issue rather than a product-wide failure [1]. That is a QC panel doing its job. It localizes the problem to a bench, a lot, or a technique at a defined time. ## The Vocabulary You Need Before Comparing Panels Buyers get burned because vendors use overlapping terms for different products. Before any commercial QC panels microbiology comparison makes sense, define the categories. **QC strain.** A well-characterized reference organism, most commonly from a recognized culture collection, with published expected values for specific tests. Standard examples used on AST benches include E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619. These strains are the backbone of antimicrobial susceptibility quality control. **QC panel.** A packaged set of QC strains or control materials, usually lyophilized or otherwise stabilized, sold as a unit with documentation, expected results, and storage and reconstitution instructions. This is the commercial product this article compares. **Reference method.** The standardized method against which commercial products are evaluated. For MIC testing, this is CLSI broth microdilution, performed in standardized cation-adjusted Mueller-Hinton broth with a defined inoculum, incubated at 35 degrees Celsius for a defined period, and read against defined endpoints [1]. **Proficiency testing (PT) or external quality assessment (EQA).** Blinded specimens or simulated patient samples sent by an external provider, processed as if they were patient material, with your results compared against peer laboratories. PT verifies the laboratory. QC panels verify the test run. A laboratory needs both. **Interlaboratory comparison.** Any structured exchange of results between laboratories, of which PT is the formal, accredited version. Informal peer comparison also drives improvement within a single institution. A quasi-experimental quality improvement project in a military emergency department showed that monthly de-anonymized report cards comparing individual clinicians against their 20 peers measurably improved adherence to facility guidelines for urinary tract and skin and soft tissue infections [2]. The same psychology applies to bench QC. Laboratories that see their QC performance ranked against peers investigate drift faster than laboratories that only track their own charts. ## Side-by-Side Comparison of Commercial QC Panel Options The table below is the core of this commercial QC panels microbiology comparison. It covers the five options a microbiology laboratory realistically chooses among. | Option | Format and contents | Primary use | Pros | Cons | |--|--|--|--|--| | Lyophilized QC organism sets for AST | Vials or cartridges of single reference strains (for example E. coli ATCC 25922, S. aureus ATCC 25923) rehydrated and plated or inoculated like an isolate | Daily QC of disk diffusion, gradient strips, and broth microdilution | Lowest cost per run, direct CLSI traceability, strain identity is fixed and documented | Requires competent subculture and inoculum preparation, results depend on technologist technique, open vials have limited shelf life | | Ready-to-use MIC panels with embedded QC wells | Commercial MIC panels or compact susceptibility panels that include dedicated QC wells or QC organisms alongside the test antimicrobials | Verification and routine QC of a commercial MIC system, especially for newly cleared or investigational agents | QC runs in the same device, same lot, same incubation as patient tests, catching lot and reader problems in one step | QC coverage is limited to the strains the manufacturer selected, endpoint definitions may differ from the reference read, panels lock you into one vendor's format | | Quantitative molecular QC panels | Stabilized preparations of nucleic acid or organism material at assigned concentrations, covering the organism types and sequence variants relevant to the assay | Run control and verification of quantitative and qualitative molecular assays | Controls the extraction, amplification, and quantification steps end to end, exposes genotype-dependent bias | Expensive, panel diversity may not match your patient population, assigned values are method-dependent | | External proficiency (PT/EQA) panels | Blinded specimens shipped periodically by an accredited provider | Periodic verification of the whole laboratory, required by accreditation | Independent assessment, peer-group benchmarking, accreditation evidence | Infrequent, cannot catch a bad lot between cycles, results arrive weeks after the run | | In-house prepared QC stocks | Laboratory-grown aliquots of reference strains, frozen at defined passage, titered in-house | Supplementing commercial panels, contingency supply, cost control in high-volume labs | Cheap at scale, tailored to the laboratory's own menu | No independent traceability once subcultured, drift risk with repeated passage, documentation burden falls entirely on the laboratory | No single option wins every row. The best commercial QC panels microbiology comparison strategy for most laboratories is layered. A lyophilized strain set or an embedded-QC panel covers daily runs. A molecular QC panel covers nucleic acid testing. PT covers the laboratory on the accreditation cycle. ## Option 1: Lyophilized QC Organism Sets ### What they are These are the workhorses of AST quality control. A supplier grows a reference strain from a documented stock, harvests it, lyophilizes it in a vial or a disc-shaped carrier, and ships it with storage conditions, rehydration instructions, and expected performance. On the bench, the technologist rehydrates the organism, adjusts the inoculum to a 0.5 McFarland standard the same way they would for a patient isolate, and runs it through the routine test. The measured MIC or zone diameter must fall in the CLSI-published QC range for that strain and drug combination. ### Pros Cost per organism is low, and the strain's identity and expected behavior are fixed by the supplier and by decades of published literature. Because the organism must pass through normal bench handling, the QC tests everything, including the technologist's inoculum technique and the incubator's actual temperature. A full set of four to six standard strains covers the major organism groups on an AST bench, which is why this format remains the default for daily disk diffusion and broth microdilution QC. ### Cons Everything upstream of the test plate is manual. A rehydration error, an aged McFarland suspension, or a warm纬 plate pour will show up as an out-of-range result with no clue about which variable failed. Documentation of passage history transfers to the laboratory the moment the strain is subcultured, which is why CLSI-style practice discourages using subcultured QC organisms for routine QC and pushes laboratories back to the original lyophilized stock at defined intervals. High-volume laboratories burn through vials quickly, and supply interruptions for a specific strain can stall a whole bench. ## Option 2: Ready-to-Use MIC Panels with Embedded QC ### What they are Some commercial susceptibility panels build QC directly into the consumable. The ComASP Cefiderocol panel evaluated in the multicenter study is the clearest published example. Each site ran the panel and CLSI broth microdilution in parallel on Enterobacterales, Acinetobacter baumannii, and P. aeruginosa clinical isolates and challenge isolates, performed its own QC with both formats, and read the panel at two different endpoints [1]. The endpoint distinction matters and is a frequent source of confusion. The CLSI read defines the MIC as the first well in which growth reduction leaves a light haze or faint turbidity rather than visible buttons or pellets. The ComASP read defines the MIC as the first well at which 100 percent inhibition of growth occurs. These are different questions asked of the same tray, and they produce different MIC distributions. ### Pros QC and patient testing share the same tray, the same lot, the same incubator, and the same reader. When the QC wells pass, you have evidence that the entire lot performed correctly that day, not just a separately prepared control plate. This shortens the distance between a QC failure and a corrective action. In the cefiderocol evaluation, reproducibility across all sites was excellent at 97.4 percent of results within one dilution of the modal MIC, and QC performance was clean at every site except for the two E. coli ATCC 25922 outliers at a single site [1]. The embedded QC therefore demonstrated that the panel format itself was controllable across geographically dispersed laboratories. The second pros is relevance to new agents. When an antimicrobial is new to the market, no laboratory has historical in-house experience with it. A commercial panel that carries the drug and its matching QC wells delivers a validated QC package on day one, which is exactly the situation in the cefiderocol study, where sites had to adopt a standardized reading and QC approach for an agent they had never run routinely [1]. ### Cons The endpoint definition is a real risk, not a footnote. In the same study, essential agreement with the reference broth microdilution method depended heavily on which read was applied. For Enterobacterales, essential agreement was 84.3 percent with the CLSI read and 95.7 percent with the ComASP read. For P. aeruginosa it was 83.3 percent versus 93.7 percent. For A. baumannii it was 78.3 percent versus 96.7 percent. A laboratory that adopts an embedded-QC panel without understanding which endpoint the manufacturer intends can generate internally consistent but systematically shifted MICs. Categorical agreement, meaning agreement with the clinical S, I, R category, was less sensitive to the read, at 92.4 percent for Enterobacterales under both reads and 89.7 percent versus 92.1 percent for P. aeruginosa [1], but a laboratory should never rely on categorical agreement to excuse a shifted MIC distribution. The second con is vendor lock-in of QC design. The embedded QC wells cover the strains the manufacturer chose. If your accreditation or your medical director requires a QC strain the panel does not include, you still need a separate lyophilized set for that agent, which means paying twice for overlapping coverage. ## Option 3: Quantitative Molecular QC Panels ### What they are Nucleic acid amplification assays and quantitative viral load assays cannot be controlled with a McFarland suspension. They require control material at a known concentration, processed through extraction and amplification alongside patient samples. Commercial molecular QC panels supply stabilized, quantified material for this purpose. ### Why panel diversity is the hard part The first generation of commercial HIV-1 [RNA quantification](/knowledge/diagnostics/molecular/rna-quantification-methods-spectrophotometry-fluorometry) assays illustrates the failure mode that molecular QC panels exist to catch. Those assays were optimized for HIV-1 subtype B, the subtype predominant in North America and Europe, and performed suboptimally on genetic variants from other regions. When a new transcription-mediated amplification based viral load assay was evaluated against a panel of primary subtype A, C, and D isolates from Kenya, alongside subtype B cloned viruses and an in-house quantitative-competitive reverse transcriptase PCR method, the new assay and a broadened version of a leading commercial assay both quantified the diverse Kenyan isolates acceptably, exposing the gap between the older commercial products and non-B subtypes [3]. The lesson for any laboratory selecting molecular QC panels is direct. A single-strain QC material will pass every day while the assay quietly underquantifies the variant your patient actually carries. Quantitative molecular QC panels should span the genetic diversity relevant to your referral population, and verification of a new molecular assay should include a challenge panel broad enough to reveal genotype-dependent bias, not merely a homologous control that mirrors the assay's own calibration material [3]. ### Pros and cons The pros are end-to-end control, quantitative tracking with Westgard-style rules if your laboratory quality management program uses them, and honest detection of reagent lot changes. The cons are cost, which rises steeply with panel diversity, and the fact that an external panel's assigned value is itself method-dependent, so comparisons across panel vendors can mislead if the assigned concentrations were established on a different platform. ## Option 4: External Proficiency and Interlaboratory Panels These are not strictly commercial QC panels, but every commercial QC panels microbiology comparison options list includes them because buyers confuse the two, and because the best PT providers also sell unblinded commercial QC materials. PT panels are blinded. Your laboratory receives simulated specimens, processes them under normal patient-testing conditions, reports results, and receives a peer-group comparison weeks later. Their strengths are independence and accreditation value. Their weaknesses are frequency and latency. A contaminated lot of media can produce a week of questionable patient results before the next PT cycle reveals anything, which is why PT supplements rather than replaces routine QC. The benchmarking aspect deserves emphasis because it changes behavior, not just paperwork. The emergency department quality improvement project cited earlier demonstrated that de-anonymized peer comparison, delivered as monthly report cards within a 20-person group, drove guideline adherence upward in a stepped-wedge design, with adherence tracked by monthly chart review over a full year [2]. Laboratories embedded in interlaboratory comparison programs get the same effect at the bench level. A laboratory that sees its AST QC z-scores drifting relative to peer laboratories has an external signal that internal charts alone will not provide for months. ## Option 5: In-House Prepared QC Stocks Some laboratories maintain their own frozen stocks of reference strains, prepared in-house from original culture collection material, titered, aliquoted, and stored at minus 70 degrees Celsius or below. This is legitimate and common in large reference laboratories. It is also the option with the highest hidden cost. Every passage away from the authenticated original introduces drift risk. The laboratory owns all traceability documentation, all titer verification, and all contingency planning if a stock dies. The practical rule is that in-house stocks are a supplement and a backup, and original commercial or culture-collection material remains the anchor for routine QC. Verification of any in-house material should mirror the layered approach used for other laboratory-made products, where in-house checks are followed by independent external evaluation. A study of in-house produced patient-specific aortic models made exactly this point, with each model passing internal quality control for deformation, then undergoing external macroscopic and electron-microscopic evaluation before clinical use [4]. The analogy holds for in-house QC organisms. Internal checks confirm what you intended to make. External reference material confirms what you actually made. ## The Criteria That Decide a Real Purchase ![Six-step purchase checklist covering regulatory fit, organism relevance, endpoint clarity, QC range documentation, format integration and supply.](/article-images/illustrations/commercial-qc-panels-microbiology-comparison-choosing-a-panel.webp) When laboratory leadership compares commercial QC panels for microbiology, the deciding criteria are rarely the ones on the vendor's front page. Use this list. 1. **Regulatory fit.** Does the panel satisfy the QC frequency and traceability your accreditation scheme and CLIA requirements demand for the specific test? A panel that is scientifically excellent but does not map to your required QC events creates work, not value. 2. **Organism relevance.** Does the panel cover the organisms on your own test menu, including the resistant phenotypes and, for molecular assays, the genotypes your patient population presents? The subtype coverage lesson from the HIV assay evaluation is the cautionary case [3]. 3. **Endpoint and read clarity.** For AST panels, does the product documentation state exactly how the MIC endpoint is defined, and does that definition match the reference method read your laboratory reports? The cefiderocol study showed essential agreement moving by more than 12 percentage points between two legitimate reading conventions on the same trays [1]. Read definitions are not trivia. 4. **QC range documentation.** Are expected results tied to named CLSI QC ranges for named strains, or only to the manufacturer's own in-house specifications? CLSI-linked ranges give your laboratory an external anchor and a defensible position during an inspection. 5. **Format integration.** Does QC run in the same consumable, lot, and reader as patient tests, or on a parallel platform? Integrated QC catches lot problems faster. Parallel QC is cheaper and more flexible. 6. **Throughput and labor.** A vial requiring rehydration, subculture the previous day, and manual inoculum adjustment costs roughly 20 minutes of skilled technologist time per run. An embedded QC well costs seconds. At 300 AST runs per week, this difference dominates total cost of ownership. 7. **Supply reliability.** Single-source strains, especially less common QC organisms, carry stockout risk that a laboratory quality management plan must absorb. ## Worked Scenarios ### Scenario 1: A community hospital adds a newly approved antimicrobial to its AST menu A 250-bed hospital's microbiology bench is cleared to report cefiderocol MICs. The laboratory has no in-house experience with the drug and no historical QC performance. The medical director chooses a commercial compact MIC panel with embedded cefiderocol QC wells rather than assembling QC from open-market lyophilized strains. The justification follows directly from the published multicenter evaluation. Sites adopting the ComASP Cefiderocol panel achieved 97.4 percent reproducibility within one dilution of the modal MIC, and QC results stayed within CLSI ranges at all sites except the two E. coli ATCC 25922 results at one site, which triggered a site-level review rather than a product withdrawal [1]. The laboratory adopts the same structure, documents the intended reading endpoint in its procedure manual, and trains every technologist on the specific endpoint definition before the first patient result is released. When one QC pair falls outside range during month two, the laboratory pulls the lot, retests from the original lyophilized stock, and documents a lot-specific corrective action, exactly the sequence the multicenter data predict will resolve most single-site QC excursions. The counterfactual is instructive. Had the laboratory instead built its own verification from hand-prepared broth microdilution trays, it would have owned the entire burden of endpoint standardization. The study data show why this burden is not trivial. The same trays read two different ways produced essential agreements separated by as much as 18 percentage points for A. baumannii, 78.3 percent versus 96.7 percent [1]. A single laboratory without a multicenter comparison would have had no external signal that its read was the problem. ### Scenario 2: A molecular laboratory brings up a new viral load platform A molecular laboratory is verifying a quantitative viral load assay whose manufacturer claims broad genotype coverage. The laboratory assembles a verification panel from commercial quantitative QC material plus a challenge set covering the sequence variants common in its referral population, and it includes an in-house reference method comparison, the same structure used when the Gen-Probe HIV-1 assay was evaluated against commercial comparators using an in-house quantitative-competitive RT-PCR and p24 antigen capture as independent anchors [3]. The verification plan deliberately includes non-homologous variants rather than only the manufacturer's calibrator-matched material. This choice is what would expose a subtype-specific quantification bias of the kind documented for early commercial HIV-1 RNA assays, which were tuned for subtype B and underperformed on other genetic forms [3]. The laboratory's QC panels continue running with every batch thereafter, and the laboratory quality management review compares monthly QC trends against peer data from its interlaboratory program, mirroring the peer-comparison effect that drove measurable improvement in the emergency department guideline study [2]. ### Scenario 3: A small laboratory chooses between buying more QC and relying on PT A physician office laboratory performs modest-volume culture and susceptibility testing and has an annual PT cycle. The director is tempted to stretch QC strain vials by subculturing them monthly. The correct comparison is not price per vial but risk per event. A subcultured QC strain can drift without any internal signal, and the next external signal arrives only at the next PT cycle, potentially months later and after affected patient results have been reported. The layered recommendation is to purchase the lyophilized set sized to the actual daily QC schedule, treat in-house subcultures only as emergency backup with documented re-verification against original stock, and treat PT as the periodic external audit it is. Interlaboratory and peer comparisons are powerful accelerators of improvement, as the military emergency department project showed with its report-card intervention, but they run on monthly-to-annual cycles and cannot police a single bad reagent lot [2]. ## Where QC Panels Fit in Laboratory Quality Management ![Comparison of daily commercial QC, manufacturer lot documentation and proficiency testing across frequency, what each verifies and what each misses.](/article-images/illustrations/commercial-qc-panels-microbiology-comparison-qc-panel-layers.webp) A commercial QC panel is one control point inside a [laboratory quality management system](/knowledge/diagnostics/emerging-tech/laboratory-quality-management-systems-a-practical-implementation-framework-for-diagnostic-labora), not the system itself. Three adjacent functions determine whether the panel's signal actually improves patient results. **Documented procedures that keep pace with reality.** Quality management treats written procedures as living documents that translate between policy and bench practice. An ethnographic study of infection prevention during the emergence of the COVID-19 crisis, based on 210 hours of observed meetings and 21 interviews at a Dutch academic hospital, found that the writing and rewriting of guidelines was a fundamental characteristic of coping with uncertainty and scarcity, with guidelines acting as mediating devices between evidence and workplace practice [5]. A microbiology QC manual behaves the same way. When a new panel, a new lot, or a new endpoint definition arrives, the procedure must be rewritten and retrained, or the QC result will be read against an obsolete expectation and misclassified as a failure. **Validation of ancillary processes, not just assays.** Microbiology quality control extends to everything that touches the specimen. A hygienic evaluation of a hospital program for recovering raw materials from recyclable medical devices examined the whole chain, from wipe disinfection at the point of accumulation through closed transport boxes to fractionated vacuum steam disinfection, and concluded that infectious risks to staff and environment were negligible [6]. The methodological point transfers directly. A laboratory that validates its AST panels but never validates its decontamination, waste, and equipment maintenance processes has QC coverage with holes in it. **Layered internal and external verification.** The aortic model study provides the template. Internal quality control for deformation, using heat map analysis across five identically printed models subjected to sterilization, disinfection, or no treatment, was followed by independent external examination with macroscopic and SEM/EDX methods before clinical deployment [4]. Microbiology QC should be structured the same way. The daily commercial panel is the internal layer. Manufacturer lot documentation and CLSI ranges are the second layer. PT and interlaboratory comparison are the external layer. A failure at any layer should trigger review of the layers below it. ## Common Mistakes and Limitations These are the specific, practical errors that recur on AST and molecular benches. 1. **Running QC but reading it against the wrong endpoint.** As the cefiderocol evaluation demonstrated, the same tray read by two conventions produces materially different MIC distributions [1]. If your procedure manual does not name the endpoint, the panel's QC wells cannot protect you. 2. **Passaging QC strains beyond the documented limit.** Every subculture away from authenticated stock is an uncontrolled experiment. Subcultured organisms are contingency material, not routine QC. 3. **Treating a PT result as QC.** PT arrives weeks later and validates the laboratory, not the run. A passing PT cycle never excuses an out-of-range daily QC on the day it occurred. 4. **Assuming a single QC strain covers assay diversity.** The HIV-1 assay history shows a commercial product passing its own controls while failing on genetic variants the controls did not represent [3]. Challenge panels must span the diversity your patients present. 5. **Chasing categorical agreement to excuse MIC shifts.** Categorical agreement can remain high while essential agreement falls, as it did for Enterobacterales at 92.4 percent categorical agreement alongside 84.3 percent essential agreement under the CLSI read [1]. Report the MIC distribution problem even when the S, I, R category happens to match. 6. **Ignoring site-level QC excursions.** The two E. coli ATCC 25922 outliers at one site in the multicenter study were a site signal, not a product signal [1]. The correct response to an isolated QC failure is local troubleshooting before contacting the vendor. 7. **Buying panels with no procedural update.** A new panel with a new read definition and no rewritten SOP produces systematic misclassification, the exact failure mode the guideline-rewriting study documented when practice outpaced documents [5]. 8. **Overlooking non-analytical processes.** Decontamination, transport, and waste handling are part of the quality chain and were shown to require their own structured validation, not assumption [6]. One honest limitation belongs on the record. Published QC evaluations, including the multicenter cefiderocol study, test the panel under controlled, well-staffed conditions across a small number of sites. A laboratory with high staff turnover, intermittent incubator verification, or an unusual patient population cannot assume the published performance transfers intact. Individual validation on your own bench, with your own lots and readers, remains mandatory before any commercial panel replaces in-house verification data. ## Frequently Asked Questions ### What is a commercial QC panel in microbiology? It is a packaged, pre-characterized set of control organisms or control materials, usually lyophilized, that a laboratory runs through its normal test process to confirm the system is performing within expected limits. Expected results are tied to published QC ranges, most commonly the CLSI ranges for reference strains such as E. coli ATCC 25922. ### How often should QC organisms be run in the microbiology laboratory? Frequency is set by your assay's clearance, the manufacturer's instructions, and your accreditation scheme, and for manual AST it is commonly every day the test is performed or with each new lot and shipment. The controlling principle is that no patient results are released from a run whose QC failed. ### Are commercial QC panels a substitute for proficiency testing? No. QC panels verify each test run at the bench, while proficiency testing is a blinded external assessment of the whole laboratory on a periodic cycle. Accreditation requires both, and each catches failures the other misses. ### Which reference strains are used for antimicrobial susceptibility QC? The standard set includes E. coli ATCC 25922, P. aeruginosa ATCC 27853, S. aureus ATCC 25923, E. faecalis ATCC 29212, and S. pneumoniae ATCC 49619, selected to cover the major organism groups on the AST menu. The applicable strains and their QC ranges for each drug are specified in CLSI standards. ### How do I choose the best commercial QC panel for my laboratory? Match the panel to your test menu, your accreditation requirements, and your throughput, then confirm that its expected values map to named CLSI QC ranges, that reading endpoints are explicitly defined, and that supply is reliable. For high-volume AST, integrated panels with embedded QC wells reduce labor, while lyophilized strain sets offer the lowest cost per run and the broadest drug coverage. ### Why did my QC result fall outside the published range even though my technique was correct? QC excursions usually trace to a reagent lot, incubation temperature, inoculum density, or reader variability rather than to deliberate error, and isolated excursions at a single site are common even in multicenter evaluations. Retest from original stock, quarantine affected patient results, and document the corrective action before releasing the run. ## Sources 1. [A multicenter performance evaluation of cefiderocol MIC results: ComASP in comparison to CLSI broth microdilution.](https://pubmed.ncbi.nlm.nih.gov/39745470/) 2. [Peer Comparison Improves Guideline Adherence for Urinary Tract Infection in a Military Emergency Department: A Quality Improvement Project.](https://pubmed.ncbi.nlm.nih.gov/42832262/) 3. [Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.](https://pubmed.ncbi.nlm.nih.gov/10878065/) 4. [Accuracy and Sterilizability of In-House Printed Patient-Specific Aortic Model for Surgeon-Modified Stent Grafts-A Workflow Description for Emergency Aortic Endovascular Procedures.](https://pubmed.ncbi.nlm.nih.gov/38592134/) 5. [Mediating scarcity in pandemic times: an ethnographic study on the prevention and control of SARS-CoV-2 infections during the emergence of the corona crisis in the Netherlands.](https://pubmed.ncbi.nlm.nih.gov/36424613/) 6. [Hygienic evaluation of the Resourcify GmbH concept for recovering raw materials from recyclable medical devices after surgery.](https://pubmed.ncbi.nlm.nih.gov/38766638/)